Despite the WHO declaring that COVID-19 was no longer a global emergency as of May 2023, there is still a significant unmet clinical need and global economic cost associated with currently circulating variants of SARS-CoV-2
BTK is a multi-peptide research formulation combining BPC-157, TB-500 (Thymosin Beta-4 fragment), and KPV, commonly examined in laboratory environments for their collective influence on cellular signaling pathways related to tissue response and inflammatory modulation
This material is sold for laboratory research use only it is not a drug, food, cosmetic, or dietary supplement, and it is not intended for human consumption, therapeutic use, diagnostic use, or veterinary use
It was originally developed with the intention of fighting obesity by stimulating lipolysis (the breakdown of fats) and inhibiting lipogenesis, the transformation of non-fat food materials into body fat